查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158714

GMP級mRNA生產市場：全球市場預測，2026-2032年

GMP-grade mRNA Production Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，GMP 級 mRNA 生產市場將成長至 88.8 億美元，複合年成長率為 21.63%。

主要市場統計數據
基準年 2025 22.5億美元
預計年份：2026年 27.4億美元
預測年份 2032 88.8億美元
複合年成長率 (%) 21.63%

GMP級mRNA產生：概述

GMP級mRNA生產是指在受控環境下，依照藥品生產品質管理規範（GMP）的要求，生產用於臨床和商業用途的傳訊RNA。此領域需要可重複的模板設計、酵素轉錄、純化、製劑、無菌處理、分析表徵以及經過驗證的品管系統。其策略重要性不僅體現在疫苗領域，也體現在治療性蛋白質、腫瘤學、罕見疾病和個人化醫療等領域。同時，監管機構也日益重視產品的一致性、製程控制、可追溯性和供應的連續性。

透過重組GMP級mRNA實現生產轉型

生產方式正從以宣傳活動為基礎的專業化生產轉向更標準化和柔軟性的平台。關鍵變化包括增強體外轉移、改進雜質去除、模組化一次性加工、封閉式系統操作，以及在批次記錄和製程監控中更多地採用自動化技術。開發人員還強調從研發早期階段就“以製造為導向的設計（DFM）”，這有助於技術轉移並減少臨床試驗各階段之間的變更。這些變化使得分析可比性、原料合格以及可擴展的填充和包裝能力成為研發策略的核心要素。

人工智慧將為mRNA生產帶來哪些變化

人工智慧 (AI) 可透過加速序列和密碼子最佳化、識別候選製劑以及檢測製程資料和品質資料之間的相關性來支援 mRNA 生產。機器學習工具在經過代表性資料集訓練並針對預期應用檢驗後，還可以幫助預測產量、雜質譜、穩定性以及製程偏差。在法規環境下，採用 AI 需要可解釋性、資料完整性管理、模型管治、網路安全以及有記錄的人工監督。短期內，其最實際的作用是為研發、製程監控和品質調查提供決策支持，而不是用於無人監督的產品放行決策。

全球生產網路中的區域洞察

北美擁有成熟的生物製藥基礎設施、先進的監管合規能力以及對快速臨床應用的強勁需求。歐洲受益於成熟的GMP專業知識和統一的科學標準，但跨境物流和產能分配仍是重要的考量。亞太地區正在加強國內生產和分析能力以及區域供應鏈的韌性，其中澳洲、中國、印度、日本和韓國各自擁有獨特的研發和生產環境。拉丁美洲在應對技術取得和人才引進等挑戰的同時，持續拓展其生物製藥能力。中東致力於生命科學領域的多元化發展並增強區域韌性，而非洲則繼續專注於建立生產、品質和技術轉移的基礎能力。

戰略集團分析：東協、金磚國家、歐盟、七國集團、海灣合作理事會、北約

東南亞國協為區域製藥生產提供了一個正在發展的平台，其優先事項專注於人力資源開發、監管協調以及建立可靠的冷鏈基礎設施。金磚國家成員國雖然國內產能水準各異，標準和基礎設施也存在顯著差異，但都能支持更廣泛的技術轉移和供應多元化目標。歐盟受益於一體化的監管和產業框架，而七國集團則在科學、金融和品管系統方面擁有先進的能力。海灣合作理事會國家正在投資醫療保健和產業多元化，為本地生產和區域分銷創造了機會。北約成員國擁有相當可觀的生物醫學和物流能力，但其在符合GMP標準的mRNA方面的合作仍很大程度上受制於各國的衛生、產業和監管政策。

各國生產和產能研究。

美國和加拿大擁有強大的轉化醫學生態系統、專業人才和完善的監管體系。德國、法國、義大利、西班牙和英國將成熟的生物製藥能力與先進的臨床和品質網路結合，歐盟框架促進了跨境合作。中國、日本和韓國在保持國內韌性的同時，擁有相當的科學研究和生產實力，並持續專注於先進療法的研發。印度正在加強其大規模製藥生產和製程開發能力。澳洲支持高品質的研發和臨床應用。巴西和墨西哥是拉丁美洲區域准入和生產發展的重要樞紐。俄羅斯擁有科學研究和製藥資源，但國際供應、合作和監管環境可能會影響業務永續營運。

為建構可靠的mRNA生產體系的領導者提供建議

領導者應從一開始就建立基於平台的營運模式，將序列設計、製程開發、分析、配方、填充/包裝和品質放行等環節連接起來。他們還應認證多個關鍵原料來源，制定完善的技術轉移方案，並為專用設備、酵素、脂質和無菌技術制定緊急時應對計畫。對先進分析、自動化和資料完整性的投資必須輔以清晰的驗證和管治。區域夥伴關係有助於加強人才培養和供應鏈韌性，而與監管機構的早期溝通則有助於明確其對等效性、新型輔料、製程變更和人工智慧工具的預期。最後，企業應採用基於風險的生產力計畫，而不是依賴單一的生產路徑。

GMP級mRNA評估的調查方法

本執行摘要對市場範圍、既定的GMP原則、生物製藥生產實踐、監管考慮以及公開認可的區域產能格局進行了定性綜合分析。分析結果依生產技術、品質系統、供應鏈要求、數位化程度、區域和組織機構進行分類。市場估算、預測、市場佔有率和公司特定聲明均未包含在內。區域、集團和國家的具體觀察僅作為戰略背景，在做出投資或營運決策之前，應根據當前的監管指南、工廠層級的能力以及專案特定的技術數據進行檢驗。

結論：韌性與管理是GMP級mRNA成功的關鍵。

GMP級mRNA生產正朝著平台化方向發展，產品品質取決於設計、原料、程式參數、分析、配方、無菌和資料系統的協調管理。儘管各地區的能力有所不同，但互聯互通程度日益提高，使得供應鏈的韌性和技術轉移與科研績效同等重要。那些能夠規範開發流程、強化品質源自於設計（QbD）實踐、在適當管治下實施人工智慧並實現關鍵投入多元化的機構，將更有能力確保其mRNA計畫在臨床和商業化方面取得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 GMP級mRNA生產市場：以mRNA類型分類

  • 常規mRNA
    • 核苷修飾型
    • 不合格的
  • 修飾的mRNA
  • 自擴增mRNA
    • 基於活病毒的
    • 非病毒

第8章：GMP級mRNA生產市場：依遞送系統分類

  • 脂質奈米顆粒
  • 基於胜肽的
  • 聚合物基

第9章：GMP級mRNA生產市場：依生產規模分類

  • 臨床量表
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業規模
  • 中試規模

第10章：GMP級mRNA生產市場：依應用分類

  • 治療
    • 基因編輯
    • 蛋白質替代療法
    • 再生醫學
  • 疫苗
    • 癌症疫苗
    • 感染疾病疫苗

第11章 GMP級mRNA生產市場：依最終用戶分類

  • 學術研究機構
  • 契約製造組織（CMO）
  • 製藥和生物技術公司

第12章 GMP級mRNA生產市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 GMP級mRNA生產市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 GMP級mRNA生產市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AGC Biologics, Inc.
  • Aldevron, LLC
  • Anemocyte, Inc.
  • ARCALIS Co., Ltd.
  • BioNTech SE
  • Catalent, Inc.
  • CordenPharma International Corp.
  • CureVac AG
  • eTheRNA immunotherapies NV
  • GenScript Biotech Corporation
  • Lonza Group AG
  • Merck KGaA
  • Moderna, Inc.
  • Porton Advanced Solutions, LLC
  • Samsung Biologics Co., Ltd.
  • ST Pharm Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies, LLC
  • Vernal Biosciences, Inc.
  • WuXi Biologics Inc.

第17章 主要專家

Product Code: MRR-4654A89DBBA5

The GMP-grade mRNA Production Market is projected to grow by USD 8.88 billion at a CAGR of 21.63% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.25 billion
Estimated Year [2026] USD 2.74 billion
Forecast Year [2032] USD 8.88 billion
CAGR (%) 21.63%

GMP-Grade mRNA Production: Executive Overview

GMP-grade mRNA production is the controlled manufacture of messenger RNA for clinical and commercial use under good manufacturing practice requirements. The field depends on reproducible template design, enzymatic transcription, purification, formulation, aseptic processing, analytical characterization, and validated quality systems. Its strategic importance is expanding beyond vaccines into therapeutic proteins, oncology, rare diseases, and personalized medicine, while regulatory expectations increasingly emphasize product consistency, process control, traceability, and supply continuity.

Manufacturing Shifts Reshaping GMP-Grade mRNA

The production landscape is moving from campaign-based, specialized manufacturing toward more standardized and flexible platforms. Key shifts include intensified in vitro transcription, improved impurity removal, modular single-use processing, closed-system operations, and greater use of automation for batch records and process monitoring. Developers are also emphasizing design-for-manufacturing earlier in development, enabling smoother technology transfer and reducing changes between clinical phases. These shifts make analytical comparability, raw-material qualification, and scalable fill-finish capabilities central to development strategy.

How Artificial Intelligence Is Changing mRNA Production

Artificial intelligence can support mRNA production by accelerating sequence and codon optimization, identifying formulation candidates, and detecting relationships across process and quality data. Machine-learning tools may also help predict yield, impurity profiles, stability, and process deviations, provided they are trained on representative datasets and validated for intended use. In regulated environments, AI adoption requires explainability, data integrity controls, model governance, cybersecurity, and documented human oversight. Its most practical near-term role is decision support for development, process monitoring, and quality investigations rather than unsupervised release decisions.

Regional Insights Across the Global Production Network

North America combines mature biopharmaceutical infrastructure, advanced regulatory capabilities, and strong demand for rapid clinical translation. Europe benefits from established GMP expertise and coordinated scientific standards, although cross-border logistics and capacity allocation remain important considerations. Asia-Pacific is strengthening domestic manufacturing, analytical capabilities, and regional supply resilience, with Australia, China, India, Japan, and South Korea representing distinct development and production environments. Latin America is expanding biopharmaceutical capabilities while continuing to address technology access and specialized workforce needs. The Middle East is pursuing life-sciences diversification and local resilience, whereas Africa remains focused on building foundational manufacturing, quality, and technology-transfer capacity.

Strategic Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN economies offer a developing regional platform for pharmaceutical manufacturing, with priorities centered on workforce development, regulatory alignment, and dependable cold-chain infrastructure. BRICS members reflect varied levels of domestic capability and can support broader technology-transfer and supply-diversification objectives, although standards and infrastructure differ materially. The European Union benefits from integrated regulatory and industrial frameworks, while the G7 provides deep scientific, financial, and quality-system capabilities. GCC countries are investing in healthcare and industrial diversification, creating opportunities for localized production and regional distribution. NATO members collectively represent substantial biomedical and logistics capacity, but collaboration on GMP-grade mRNA remains primarily shaped by national health, industrial, and regulatory policies.

Country-Level Production and Capability Considerations

The United States and Canada offer strong translational ecosystems, specialized talent, and sophisticated regulatory infrastructure. Germany, France, Italy, Spain, and the United Kingdom combine established biopharmaceutical capabilities with advanced clinical and quality networks, while the European Union context supports cross-border coordination. China, Japan, and South Korea maintain substantial scientific and manufacturing depth, with continued emphasis on domestic resilience and advanced therapeutics. India is strengthening large-scale pharmaceutical and process-development capabilities. Australia supports high-quality research and clinical translation. Brazil and Mexico are important Latin American anchors for regional access and manufacturing development. Russia retains scientific and pharmaceutical assets, though international supply, collaboration, and regulatory conditions can affect operating continuity.

Actions for Leaders Building Reliable mRNA Manufacturing

Leaders should build a platform-based operating model that links sequence design, process development, analytics, formulation, fill-finish, and quality release from the outset. They should qualify multiple critical raw-material sources, document robust technology-transfer packages, and establish contingency plans for specialized equipment, enzymes, lipids, and sterile operations. Investment in advanced analytics, automation, and data integrity should be paired with clear validation and governance. Regional partnerships can strengthen workforce development and supply resilience, while early regulatory engagement can clarify expectations for comparability, novel excipients, process changes, and AI-enabled tools. Finally, organizations should use risk-based capacity planning rather than relying on a single manufacturing pathway.

Research Methodology for the GMP-Grade mRNA Assessment

This executive summary uses a qualitative synthesis of the supplied market scope, established GMP principles, biopharmaceutical manufacturing practices, regulatory considerations, and publicly recognized regional capability patterns. The analysis organizes findings across production technologies, quality systems, supply-chain requirements, digitalization, geography, and institutional groupings. It intentionally excludes market estimates, market shares, forecasts, and company-specific claims. Regional, group, and country observations are framed as strategic context and should be validated against current regulatory guidance, facility-level capabilities, and project-specific technical data before investment or operational decisions.

Conclusion: Resilience and Control Define GMP-Grade mRNA Success

GMP-grade mRNA production is becoming a platform discipline in which product quality depends on the coordinated control of design, materials, process parameters, analytics, formulation, aseptic handling, and data systems. Regional capabilities are uneven but increasingly interconnected, making supply resilience and technology transfer as important as scientific performance. Organizations that standardize development, strengthen quality-by-design practices, adopt AI with appropriate governance, and diversify critical inputs will be better positioned to advance mRNA programs reliably across clinical and commercial requirements.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. GMP-grade mRNA Production Market, by mRNA Type

  • 7.1. Introduction
  • 7.2. Conventional mRNA
    • 7.2.1. Nucleoside Modified
    • 7.2.2. Unmodified
  • 7.3. Modified mRNA
  • 7.4. Self Amplifying mRNA
    • 7.4.1. Live Virus Based
    • 7.4.2. Non Viral

8. GMP-grade mRNA Production Market, by Delivery System

  • 8.1. Introduction
  • 8.2. Lipid Nanoparticle
  • 8.3. Peptide Based
  • 8.4. Polymer Based

9. GMP-grade mRNA Production Market, by Production Scale

  • 9.1. Introduction
  • 9.2. Clinical Scale
    • 9.2.1. Phase I
    • 9.2.2. Phase II
    • 9.2.3. Phase III
  • 9.3. Commercial Scale
  • 9.4. Pilot Scale

10. GMP-grade mRNA Production Market, by Application

  • 10.1. Introduction
  • 10.2. Therapeutics
    • 10.2.1. Gene Editing
    • 10.2.2. Protein Replacement Therapy
    • 10.2.3. Regenerative Medicine
  • 10.3. Vaccines
    • 10.3.1. Cancer Vaccines
    • 10.3.2. Infectious Disease Vaccines

11. GMP-grade mRNA Production Market, by End User

  • 11.1. Introduction
  • 11.2. Academic and Research Institutes
  • 11.3. Contract Manufacturing Organization
  • 11.4. Pharmaceutical Biotechnology Companies

12. GMP-grade mRNA Production Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. GMP-grade mRNA Production Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. GMP-grade mRNA Production Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AGC Biologics, Inc.
  • 16.2. Aldevron, LLC
  • 16.3. Anemocyte, Inc.
  • 16.4. ARCALIS Co., Ltd.
  • 16.5. BioNTech SE
  • 16.6. Catalent, Inc.
  • 16.7. CordenPharma International Corp.
  • 16.8. CureVac AG
  • 16.9. eTheRNA immunotherapies NV
  • 16.10. GenScript Biotech Corporation
  • 16.11. Lonza Group AG
  • 16.12. Merck KGaA
  • 16.13. Moderna, Inc.
  • 16.14. Porton Advanced Solutions, LLC
  • 16.15. Samsung Biologics Co., Ltd.
  • 16.16. ST Pharm Co., Ltd.
  • 16.17. Thermo Fisher Scientific Inc.
  • 16.18. TriLink BioTechnologies, LLC
  • 16.19. Vernal Biosciences, Inc.
  • 16.20. WuXi Biologics Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global GMP-grade mRNA Production Market, Years Considered for the Study
  • FIGURE 2. Global GMP-grade mRNA Production Market, Research Design
  • FIGURE 3. Global GMP-grade mRNA Production Market, Research Framework
  • FIGURE 4. Global GMP-grade mRNA Production Market, Data Triangulation
  • FIGURE 5. Global GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global GMP-grade mRNA Production Market Size, by mRNA Type, 2025 vs 2032 (%)
  • FIGURE 7. Global GMP-grade mRNA Production Market Size, by mRNA Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global GMP-grade mRNA Production Market Size, by Delivery System, 2025 vs 2032 (%)
  • FIGURE 9. Global GMP-grade mRNA Production Market Size, by Delivery System, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global GMP-grade mRNA Production Market Size, by Production Scale, 2025 vs 2032 (%)
  • FIGURE 11. Global GMP-grade mRNA Production Market Size, by Production Scale, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global GMP-grade mRNA Production Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global GMP-grade mRNA Production Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global GMP-grade mRNA Production Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global GMP-grade mRNA Production Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global GMP-grade mRNA Production Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global GMP-grade mRNA Production Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global GMP-grade mRNA Production Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global GMP-grade mRNA Production Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global GMP-grade mRNA Production Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global GMP-grade mRNA Production Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global GMP-grade mRNA Production Market Segmentation & Coverage
  • TABLE 2. Global GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 4. Global Conventional mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Conventional mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Conventional mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Nucleoside Modified Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Nucleoside Modified Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Nucleoside Modified Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Unmodified Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Unmodified Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Unmodified Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Modified mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Modified mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Modified mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Self Amplifying mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Self Amplifying mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Self Amplifying mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Live Virus Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Live Virus Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Live Virus Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Non Viral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Non Viral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Non Viral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 26. Global Lipid Nanoparticle Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Lipid Nanoparticle Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Lipid Nanoparticle Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Peptide Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Peptide Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Peptide Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Polymer Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Polymer Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Polymer Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 36. Global Clinical Scale Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Clinical Scale Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Clinical Scale Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Commercial Scale Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Commercial Scale Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Commercial Scale Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Pilot Scale Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Pilot Scale Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Pilot Scale Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 55. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Gene Editing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Gene Editing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Gene Editing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Protein Replacement Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Protein Replacement Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Protein Replacement Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Regenerative Medicine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Regenerative Medicine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Regenerative Medicine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Infectious Disease Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Infectious Disease Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Infectious Disease Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 77. Global Academic and Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Academic and Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Academic and Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Contract Manufacturing Organization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Contract Manufacturing Organization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Contract Manufacturing Organization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Pharmaceutical Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Pharmaceutical Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Pharmaceutical Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global GMP-grade mRNA Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific GMP-grade mRNA Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 96. Asia-Pacific GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 97. Asia-Pacific GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 98. North America GMP-grade mRNA Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. North America GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 100. North America GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 101. North America GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 102. North America GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 103. North America GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 104. North America GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 105. North America GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 106. North America GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 107. North America GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 108. North America GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 109. Latin America GMP-grade mRNA Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 110. Latin America GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 111. Latin America GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 112. Latin America GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 113. Latin America GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 114. Latin America GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 115. Latin America GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 116. Latin America GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 117. Latin America GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 118. Latin America GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 119. Latin America GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 120. Europe GMP-grade mRNA Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Europe GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 122. Europe GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 123. Europe GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 124. Europe GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 125. Europe GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 126. Europe GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 127. Europe GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 128. Europe GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 129. Europe GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 130. Europe GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 131. Middle East GMP-grade mRNA Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 132. Middle East GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 133. Middle East GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 134. Middle East GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 135. Middle East GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 136. Middle East GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 137. Middle East GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 138. Middle East GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 139. Middle East GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 140. Middle East GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 141. Middle East GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 142. Africa GMP-grade mRNA Production Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 143. Africa GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 144. Africa GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 145. Africa GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 146. Africa GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 147. Africa GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 148. Africa GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 149. Africa GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 150. Africa GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 151. Africa GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 152. Africa GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 153. Global GMP-grade mRNA Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 154. ASEAN GMP-grade mRNA Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 155. ASEAN GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 156. ASEAN GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 157. ASEAN GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 158. ASEAN GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 159. ASEAN GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 160. ASEAN GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 161. ASEAN GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 162. ASEAN GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 163. ASEAN GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 164. ASEAN GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 165. GCC GMP-grade mRNA Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 166. GCC GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 167. GCC GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 168. GCC GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 169. GCC GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 170. GCC GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 171. GCC GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 172. GCC GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 173. GCC GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 174. GCC GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 175. GCC GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 176. European Union GMP-grade mRNA Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 177. European Union GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 178. European Union GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 179. European Union GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 180. European Union GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 181. European Union GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 182. European Union GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 183. European Union GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 184. European Union GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 185. European Union GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 186. European Union GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. BRICS GMP-grade mRNA Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 188. BRICS GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 189. BRICS GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 190. BRICS GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 191. BRICS GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 192. BRICS GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 193. BRICS GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 194. BRICS GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 195. BRICS GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 196. BRICS GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 197. BRICS GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 198. G7 GMP-grade mRNA Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 199. G7 GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 200. G7 GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 201. G7 GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 202. G7 GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 203. G7 GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 204. G7 GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 205. G7 GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 206. G7 GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 207. G7 GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 208. G7 GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 209. NATO GMP-grade mRNA Production Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 210. NATO GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 211. NATO GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 212. NATO GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 213. NATO GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 214. NATO GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 215. NATO GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 216. NATO GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 217. NATO GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 218. NATO GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 219. NATO GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 220. Global GMP-grade mRNA Production Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 221. United States GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 222. United States GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 223. United States GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 224. United States GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 225. United States GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 226. United States GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 227. United States GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 228. United States GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 229. United States GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 230. United States GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 231. United States GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 232. Canada GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 233. Canada GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 234. Canada GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 235. Canada GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 236. Canada GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 237. Canada GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 238. Canada GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 239. Canada GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 240. Canada GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 241. Canada GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 242. Canada GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 243. Mexico GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 244. Mexico GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 245. Mexico GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 246. Mexico GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 247. Mexico GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 248. Mexico GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 249. Mexico GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 250. Mexico GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 251. Mexico GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 252. Mexico GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 253. Mexico GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 254. Brazil GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 255. Brazil GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 256. Brazil GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 257. Brazil GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 258. Brazil GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 259. Brazil GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 260. Brazil GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 261. Brazil GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 262. Brazil GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 263. Brazil GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 264. Brazil GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 265. United Kingdom GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 266. United Kingdom GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 267. United Kingdom GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 268. United Kingdom GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 269. United Kingdom GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 270. United Kingdom GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 271. United Kingdom GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 272. United Kingdom GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 273. United Kingdom GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 274. United Kingdom GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 275. United Kingdom GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 276. Germany GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 277. Germany GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 278. Germany GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 279. Germany GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 280. Germany GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 281. Germany GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 282. Germany GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 283. Germany GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 284. Germany GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 285. Germany GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 286. Germany GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 287. France GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 288. France GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 289. France GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 290. France GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 291. France GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 292. France GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 293. France GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 294. France GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 295. France GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 296. France GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 297. France GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 298. Russia GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 299. Russia GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 300. Russia GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 301. Russia GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 302. Russia GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 303. Russia GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 304. Russia GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 305. Russia GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 306. Russia GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 307. Russia GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 308. Russia GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 309. Italy GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 310. Italy GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 311. Italy GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 312. Italy GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 313. Italy GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 314. Italy GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 315. Italy GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 316. Italy GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 317. Italy GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 318. Italy GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 319. Italy GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 320. Spain GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 321. Spain GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 322. Spain GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 323. Spain GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 324. Spain GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 325. Spain GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 326. Spain GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 327. Spain GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 328. Spain GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 329. Spain GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 330. Spain GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 331. China GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 332. China GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 333. China GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032 (USD Million)
  • TABLE 334. China GMP-grade mRNA Production Market Size, by Self Amplifying mRNA, 2017-2032 (USD Million)
  • TABLE 335. China GMP-grade mRNA Production Market Size, by Delivery System, 2017-2032 (USD Million)
  • TABLE 336. China GMP-grade mRNA Production Market Size, by Production Scale, 2017-2032 (USD Million)
  • TABLE 337. China GMP-grade mRNA Production Market Size, by Clinical Scale, 2017-2032 (USD Million)
  • TABLE 338. China GMP-grade mRNA Production Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 339. China GMP-grade mRNA Production Market Size, by Therapeutics, 2017-2032 (USD Million)
  • TABLE 340. China GMP-grade mRNA Production Market Size, by Vaccines, 2017-2032 (USD Million)
  • TABLE 341. China GMP-grade mRNA Production Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 342. India GMP-grade mRNA Production Market Size, 2017-2032 (USD Million)
  • TABLE 343. India GMP-grade mRNA Production Market Size, by mRNA Type, 2017-2032 (USD Million)
  • TABLE 344. India GMP-grade mRNA Production Market Size, by Conventional mRNA, 2017-2032